08:04 AM EDT, 08/14/2024 (MT Newswires) -- Verrica Pharmaceuticals ( VRCA ) shares surged 26% in recent premarket activity Wednesday after it reported preliminary positive results from the second part of a phase 2 trial of VP-315 to treat basal cell carcinoma.

The dermatology therapeutics company said that among the encouraging results, VP-315 was well tolerated with no reported treatment-related serious adverse events and that all patients in the trial had a reduction in tumor size with an overall reduction of approximately 86%.

Verrica said it expects immune response data in Q1 of 2025, and that it will request an end-of-phase 2 meeting with the US Food and Drug Administration to determine the next steps to develop VP-315 in H1 of 2025.

Price: 6.76, Change: +1.49, Percent Change: +28.27